We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.0% | 32.50 | 108,213 | 12:41:24 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 32.00 | 33.00 | 32.50 | 32.25 | 32.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 27.17M | -26.94M | -0.0746 | -4.36 | 117.41M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:46:15 | O | 2,000 | 32.31 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 07/11/2023 | 07:00 | UKREG | Creo Medical Group PLC Capital Markets Day |
| 01/11/2023 | 07:00 | UKREG | Creo Medical Group PLC Speedboat(R) UltraSlim: US FDA Clearance |
| 25/10/2023 | 12:41 | ALNC |  Creo Medical says EU launch of SpeedBoat UltraSlim device accelerated |
| 25/10/2023 | 06:00 | UKREG | Creo Medical Group PLC SB UltraSlim: EU launch accelerated by 18 months |
| 16/10/2023 | 09:16 | UKREG | Creo Medical Group PLC Change of Nominated Adviser and Joint Broker |
| 12/10/2023 | 06:00 | RNSNON | Creo Medical Group PLC Investor Presentation |
| 12/9/2023 | 10:47 | ALNC | Creo Medical hails Speedboat Inject device as interim loss narrows |
| 12/9/2023 | 06:00 | UKREG | Creo Medical Group PLC Half-year Report |
| 05/9/2023 | 06:00 | UKREG | Creo Medical Group PLC Notice of Results |
| 16/8/2023 | 11:11 | ALNC | Creo Medical says NHS hospital uptake for service "fastest time" ever |
Creo Medical (CREO) Share Charts1 Year Creo Medical Chart |
|
1 Month Creo Medical Chart |
Intraday Creo Medical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 28/11/2023 | 22:15 | Creo Medical Group PLC 2023 | 304 |
| 08/6/2023 | 15:55 | Creo Medical Group... 2017 | 623 |
| 03/12/2018 | 12:41 | First use of Speedboat in mainland Europe | - |
| 09/12/2016 | 14:52 | China Real Estate Opportunities | 3 |
| 27/6/2012 | 11:52 | having a look...... | 1,095 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 03/12/2023 08:20 by Creo Medical Daily Update Creo Medical Group Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker CREO. The last closing price for Creo Medical was 32.50p.Creo Medical currently has 361,251,418 shares in issue. The market capitalisation of Creo Medical is £117,406,711. Creo Medical has a price to earnings ratio (PE ratio) of -4.36. This morning CREO shares opened at 32.50p |
Posted at 12/10/2023 09:36 by xxxxxy Creo Medical Group PLC Investor PresentationSource: |
Posted at 09/10/2023 12:12 by xxxxxy Creo Medical Group PLC (AIM:CREO), a medical device firm specialising in minimally invasive surgical endoscopy, said that the Royal Oldham Hospital has swiftly adopted its CROMA and Speedboat Inject technologies.In May, the Royal Oldham became the first NHS institution to adopt these tools across multiple endoscopy rooms, scheduling regular Speedboat submucosal dissection(SSD) case |
Posted at 17/9/2023 12:15 by dr biotech In contrast to most listed firms, Creo Medical doesn’t like its inventions to make a splash. Instead, it aims for its medical products — which use microwaves and other wireless technologies to precisely stem bleeding and cut lesions via endoscopies — to leave minimal impact.Unfortunately for Creo’s investors, the Aim-listed firm’s shares have suffered worse than minimal impact. The stock has halved in value over the past 12 months, from 65p last September to 32p now. It’s up since a February nadir of 18p amid funding concerns, but the stock is still changing hands at well below the £2 mark seen in 2021. Its current market capitalisation is just £115 million. Yet Creo’s concerns have largely eased: a £34 million fundraiser in March should provide enough cash until at least 2025, when management predicts it will turn profitable. Furthermore, the firm’s medical technology developments — which result in quicker surgeries and faster recovery, freeing up beds and so reducing bills for the health service — are bang on current NHS trends. At its interim results last week, the firm flagged a sharp increase in adoption of its Speedboat Inject device, which facilitates the removal of bowel sections with pre-cancerous growths under sedation, so patients leave hospital on the same day. A traditional removal under general anaesthetic involves up to five days in hospital. This is all modest for now. Of Creo’s £15.7 million revenues in the first half, the vast majority stemmed from its endotherapy consumable business — catheters, tubes, valves — and only £900,000 came from its “advanced energy” products. But the rate of sales doubled over the year. There are only 115 trained users of its tech, but that’s up 44 per cent on 2022. Creo’s underlying loss of £9.2 million for the half was 15 per cent lower than With £17 million cash on the balance sheet, its work is being noticed. Medics at a leading gastro industry event, Digestive Disease Week, heard this year that Creo’s technology reported an 82 per cent curative rate for bowel and colon lesions, with no recorded perforations. Nice, the health watchdog, has selected Speedboat Inject for a review that could lead to a significant UK rollout. Craig Gulliford, its chief executive, flags the “rapid pace of adoption of Creo’s technology and the global recognition it is achieving, with the body of data supporting the clinical and commercial benefits growing quickly as a result”. City analysts agree on this momentum: Chris Donnellan at the rebranded broker Cavendish reckons the firm is at an “inflection point”. Buy. |
Posted at 16/8/2023 06:10 by someuwin 16 August 2023Creo Medical Group plc ("Creo" the "Company" or the "Group") Royal Oldham SSD service going from strength to strength 40 cases completed in record time, with patients and waiting lists experiencing immediate benefits Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, provides an update on the implementation of its technology within The Royal Oldham Hospital ("Royal Oldham"). On 17 May, Creo announced that Royal Oldham had become the first NHS hospital to immediately implement CROMA and Speedboat(TM) Inject across multiple endoscopy rooms, putting in place weekly lists for multiple SSD (Speedboat Submucosal Dissection) cases. The hospital has now treated over 40 patients using the new service, representing the fastest time for any NHS hospital to reach the landmark, with exceptional results for patients, the hospital and its staff. Multiple doctors at the hospital have already progressed through Creo's Pioneer Programme mentoring stage and are independently treating regular lists of patients presenting with complex, high-risk lesions in the colon. Creo has a target base for the Speedboat range of products of more than 350 NHS hospitals, with each SSD procedure demonstrated to save the NHS up to GBP10k when compared to traditional surgery, alongside a typically far shorter hospital stay and significantly lower risk of complications. There are 23 NHS England healthcare settings that have now adopted SSD. Dr Sal Khalid, Consultant Gastroenterologist at the Royal Oldham Hospital, said: "I'm very pleased with the outcomes the Speedboat Inject device is facilitating for our patients, allowing our advanced endoscopists to remove complex high-risk lesions and even early cancer without the patient requiring invasive surgical treatment. "Almost all bowel cancers start as a lesion, and so having the technology now available to us to cut deeper and more safely through the layers of the bowel when removing a lesion enables us to ensure that it's completely removed and reduce the chances of patients requiring an operation. "It's already clear that this will have a lasting effect, with the treatment reducing the chances of recurrence from 15% to 1% and potentially providing a cure for lesions containing early cancer without requiring operation. "Indeed, only three months into the new service we are already recording a reduction in the waiting lists not only across our endoscopy suites but, perhaps most importantly, in terms of those waiting for the surgical treatment of more invasive cancers. "The best part about the new service is being able to call a patient a few days later and tell them that they have had a curative outcome - that the lesion has been removed with the necessary margins not to have to worry about it anymore. That was rarely the case before we introduced Speedboat Inject and the advanced energy. " The establishment of this service will help us maintain our status as one of the leading advanced endoscopy services in the country and help us move towards our goal of prevention, early detection, and treatment of bowel cancer." Dr Khalid has now completed over 15 procedures using the Speedboat Inject device. Out of the first 10 cases, two were confirmed as cancers and three as showing features of high grade dysplasia, suggesting lesions very close to turning into a cancer. All of these lesions were successfully removed completely through an SSD procedure using Creo's advanced energy device. What next? -- SSD will become Royal Oldham's treatment of choice for high-risk polyps suspected of containing early cancer. Hundreds of patients every year are expected to benefit from this treatment option. -- Royal Oldham plans to expand the service and increase the number of conditions it can treat using this equipment. This will involve training endoscopists to perform a wider array of procedures using CROMA and Speedboat. -- An expanded service will be supported by a dedicated multidisciplinary team involving experts from across all the relevant specialties, ensuring every patient gets the best treatment based on expert knowledge, with every decision supported by the most current medical evidence. -- Royal Oldham will also aim to offer training opportunities to help teach this advanced technique to a wider pool of doctors, including the establishment of training posts of Endoscopy Fellows who will receive dedicated training and experience of decision making and performing SSD procedures under direct supervision of Dr Sal Khalid and his team. Craig Gulliford, CEO of Creo Medical said: "Oldham provides a phenomenal model for what's possible when a hospital immediately recognises the potential of the device and implements the right pathways and resource to maximise its impact. "To know that there are 40 patients in and around Oldham who have already benefited from our technology and the excellent service provided by Dr Khalid and his team is incredibly gratifying, with the knock-on positive effects on waiting lists and hospital resources now well established. "To hear plans for the further expansion of the service is also excellent news and we look forward to supporting the hospital in every way we can." |
Posted at 04/8/2023 09:59 by master investor Edison coverage"Creo Medical - Entering phase of accelerating growth inflectionFY22 was a key inflection period for Creo with significant traction in the adoption of Speedboat Inject (its flagship electrosurgical device) and its proprietary CROMA technology platform, reflected in major robotic deals with Intuitive Surgical and CMR Surgical. Total revenue growth (8% y-o-y to £27.2m) was in line with consensus (£27m) and was primarily driven by Creo's core technology business. Operating losses rose to £30.8m, affected by increased personnel and R&D expenses, although management expects a sharp reduction from FY23 following cost-optimisation measures implemented in H222. We expect further expansion of the Speedboat Inject user base (with an emphasis on training enrolment) to be the strategic priority in FY23. With the recent fund-raise of £33.7m (gross) in Q123, we estimate the company is funded to operational profitability in H126. Incorporating the improved cash balance post the reporting period, our valuation increases to £528m (150p/share) from £493m."Cenkos coverage"Investment thesis We believe Creo Medical is at a significant inflection point in its development, with an increasing number of core Creo device users undertaking procedures on a regular basis, two Kamaptive licensing agreements announced and regional expansion of its consumables business underway. With the near-term cash concerns resolved following the recent equity raise, we expect the shares to perform strongly. We maintain our Buy recommendation." |
Posted at 26/6/2023 12:22 by someuwin Interesting tweets just now from CREO regarding todays Gov announcement on Lung Cancer screening.Creo Medical @CreoMedical ·1m "The strides being taken in lung cancer screening in the UK is very good news indeed. The sooner and more accurately it can be detected, the better the treatment options for the patient." Creo Medical @CreoMedical ·2m Replying to @CreoMedical "We are excited about what the future may hold as we look to introduce our innovative ablation technology as an additional line of treatment." |
Posted at 26/6/2023 06:11 by someuwin RNS Number : 8157DCreo Medical Group PLC 26 June 2023 Creo Medical Group plc ("Creo" the "Company" or the "Group") First upper GI Speedboat procedure in Europe completed days after clearance Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that Dr Adolfo Parra-Blanco, from Nottingham University Hospital NHS Trust has become the first clinician to perform an upper Gastrointestinal ("GI") tract Speedboat Inject case in Europe since clearance was gained last week. The procedure saw a 7cm x 5cm cancerous lesion in the stomach removed en-bloc (in one piece) in a little under two hours and was performed after Dr Parra-Blanco led an Upper GI Endoscopy Education and Training Day at the University of Nottingham, where he was able to familiarise himself with the Speedboat Inject device for use in the upper GI tract. The result of the procedure was excellent, with the patient leaving hospital shortly after. A second doctor is now also trained to use Speedboat Inject for Upper GI procedures at Nottingham, and Nottingham University Hospital NHS Trust led Upper GI ESD courses showcasing Speedboat are set to take place next week (June 28-30) and in August at Queens Medical Centre, Nottingham. Creo will continue to work closely with Nottingham University Hospital NHS Trust to support the training, mentoring and adoption of the device by numerous upper GI specialists over the coming months. This will be in conjunction with Creo's Pioneer training programme, with the Company expecting a rapid adoption of the device for upper GI procedures over the coming months. Dr Parra-Blanco said: "To have this technology now open to us for use in the upper GI in Europe is fantastic. What's clear to me is how well suited the Speedboat Inject device is for these types of procedures, and I foresee it dramatically increasing the number of patients able to benefit from this advanced energy, not only here in Nottingham but at healthcare settings elsewhere across Europe." Craig Gulliford, Chief Executive Officer of Creo Medical said: "To have the first case completed at such a well-respected and prestigious endoscopic centre, renowned for its upper GI services, so soon after clearance demonstrates both the appetite for the device to be used in the upper GI tract in Europe and the ability for clinicians to quickly get optimal results once they are familiar with the advanced energy. We look forward to continuing to work with Nottingham University Hospital NHS Trust and others to maximise the roll out of the device in the entire GI tract." |
Posted at 21/6/2023 13:37 by someuwin ...So looking back, HOYA Group PENTAX Medical were a Strategic early investor in CREO at the time of their IPO in 2016.At that time David Woods was Chief Marketing officer at HOYA Group PENTAX Medical following senior roles as President and Vice President of sales of the Americas. and was installed as Non-Executive Director on the CREO board. In 2020 David Woods left Pentax and became Executive Director of CREO. David Woods commented: "I am very fortunate to have worked with a company as great as PENTAX Medical for more than two decades and to have worked with such terrific people. It is certainly an experience where I have learned so much. Making the decision to leave was incredibly difficult, but I am enormously excited by the opportunity that Creo presents as we see increased commercial momentum from Creo's first products and the commercial launch of a wider suite of medical devices that will radically change the way endoscopists and surgeons treat patients worldwide." So whether Pentax still have a holding in CREO I don't know. But there is clearly a big link between the two companies so I wouldn't be surprised if they bid for CREO at some stage. |
Posted at 20/6/2023 13:34 by someuwin The most likely candidate to buy CREO is Pentax Medical (part of Japanese giant Hoya).They bought 6% of CREO some time ago and put one of their men on the board. Their holding has diluted to less than 3% now so doesn't show up, but I believe they are still there and could pounce at any stage. Note also CREO Chief Commercial Officer David Woods' history... David Woods Chief Commercial Officer David joined Creo as CCO in August 2020, having previously sat on Creo’s Board as a Non-Executive Director. David provides leadership and strategic direction for Creo’s commercial divisions, overseeing all strategic global commercial activities. David is an industry veteran within the MedTech sector. His experience encompasses Gastroenterology, General and Orthopaedic Surgery, Pulmonology and Ear, Nose and Throat. Prior to joining Creo, David was the President and CEO of PENTAX Americas and M&A Director of Hoya Corporation, Pentax Life Care Division. David brings significant operating and commercial experience, market understanding and a proven track record of achievement to Creo. He has also previously sat on multiple MedTech boards over the years. He was awarded the American Society for Gastrointestinal Endoscopy President’s Award in 2010, recognising exceptional contributions to the society and its mission. |
Posted at 30/1/2023 08:51 by bodgeman From what I have read people are suggesting creo require a fund raise of between 15 to 25million to carry on past june - when their money runs out at current burn rates. Let's say its 25m. If the share price were to drop to 15p then market cap of creo would be roughly the same as their upper fund raise requirement.Options - raise new capital against value of company. Who is going to do that. It makes no sense at the level required. Share issue with 90+% dilution. Makes no sense either. Unlikely there are sufficient grants or fund options with the welsh assembly. I'm sure there are lots of other improbable scenarios. If you had 25m and were considering funding creo then you would wait till the share price drops to 15p where you could almost buy creo outright or gain a controlling share for half of that and use the rest to fund their continuation past june. This would inevitably go hand in hand with cost cutting - smaller premises, smaller staff numbers. Ugly. The most sensible option (for me) would be for a competitor or current partner to buy them out OR for a fund to buy them up,fund them through to 2026 when they start to turn a profit and sell on. Where does this leave shareholders? Something is going to give soon..... |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
